The difference though is that this treatment would require hundreds of hours of ongoing work from medical professionals for each treatment. What they did was use single cell RNA sequencing to determine which subpopulations of cells are supposed to connect and where, before stimulating cell growth and guiding each RNA mapped subpopulation to where it’s roughly supposed to go. That’s one thing for anatomically complete sub-millimeter spinal cord injuries in mice, but a massive endeavor for human spinal cords.

If you’ve seen the bioengineered cancer treatments where researchers grow immune cells to target a single individual’s tumor, the amount of specialized work that goes into that pales to what current technology would require for this sort of spinal regeneration, and that’s for relatively simple small scale lesions. Multiple lesions or large scale cell death could result in attempting to selectively guide millions of microscopic axons in neat clusters for over a foot.

I wouldn’t be surprised if insurance companies refused to pay for cell regrowth, and instead went for implants that are comparatively much simpler to install and modify in brain-computer interfaces that skip over the damage. This is a great advancement and does open the door for recovering from spinal cord damage, but this is one of those treatments that people are going to get because they need to fill FDA trials and won’t charge, or because the patient is filthy rich.